Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P55899

UPID:
FCGRN_HUMAN

ALTERNATIVE NAMES:
IgG Fc fragment receptor transporter alpha chain; Neonatal Fc receptor

ALTERNATIVE UPACC:
P55899; Q5HYM5; Q9HBV7; Q9NZ19

BACKGROUND:
IgG receptor FcRn large subunit p51, alternatively named Neonatal Fc receptor, is crucial for transferring immunity from mother to newborn by mediating IgG uptake from milk. It ensures lifelong humoral immunity by recycling IgG, thus prolonging its presence in the bloodstream. This receptor also plays a role in the homeostasis of albumin, the most abundant circulating protein, underscoring its systemic importance in protein regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of IgG receptor FcRn large subunit p51 offers a pathway to novel therapeutic avenues. Its key role in immune response and protein regulation makes it a target for developing treatments for immune deficiencies and disorders related to protein imbalance.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.